Kyverna Therapeutics, Inc.
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$161.3M
- Total assets
- $293.8M
- Market cap
- $454.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $169.8M
- Operating income
- -$169.8M
- Income tax
- $0
- Net income
- -$161.3M
- EPS (basic)
- $-3.64
- EPS (diluted)
- $-3.64
Balance sheet
- Total assets
- $293.8M
- Current assets
- $283.0M
- Total liabilities
- $61.5M
- Current liabilities
- $36.5M
- Shareholders’ equity
- $232.3M
Cash flow
- Operating cash flow
- -$153.7M
- Investing cash flow
- $40.0M
- Financing cash flow
- $141.2M
- Net cash flow
- $27.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $454.1M
- EPS (diluted)
- $-3.64
- Shares outstanding
- 58.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 8, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $161.3M.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kyverna Therapeutics, Inc..
Write a review
News about Kyverna Therapeutics, Inc.
News & sentiment via Polygon.io
